241 related articles for article (PubMed ID: 20003286)
41. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
42. Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
Koskas M; Depreeuw J; Moens S; Annibali D; Cuppens T; Moerman P; Lambrechts D; Amant F
Anticancer Res; 2016 Oct; 36(10):5381-5384. PubMed ID: 27798902
[TBL] [Abstract][Full Text] [Related]
43. Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis.
Khoury T; Kanehira K; Wang D; Ademuyiwa F; Mojica W; Cheney R; Morrison C; Conroy J; Nowak N; Liu S
Mod Pathol; 2010 Oct; 23(10):1364-78. PubMed ID: 20657551
[TBL] [Abstract][Full Text] [Related]
44. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Villa A; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Lombardi AV; Sorio R; Mangili G; Priolo D; Magni G; Morabito A
BMC Cancer; 2008 Sep; 8():252. PubMed ID: 18761742
[TBL] [Abstract][Full Text] [Related]
45. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
[TBL] [Abstract][Full Text] [Related]
46. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of the intestinal type.
Miller K; Millar J; McCluggage WG
Am J Surg Pathol; 2011 Sep; 35(9):1331-6. PubMed ID: 21836488
[TBL] [Abstract][Full Text] [Related]
47. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
49. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
Haq B; Geyer CE
Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
[TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
51. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
[TBL] [Abstract][Full Text] [Related]
52. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
54. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N
Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
[TBL] [Abstract][Full Text] [Related]
55. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.
Risio M; Casorzo L; Redana S; Montemurro F
Oncol Rep; 2005 Feb; 13(2):305-9. PubMed ID: 15643516
[TBL] [Abstract][Full Text] [Related]
56. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
57. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
58. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
59. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
60. HER2 status in breast cancer: experience of a Spanish National Reference Centre.
Cuadros M; Cano C; López FJ; Talavera P; García-Peréz I; Blanco A; Concha Á
Clin Transl Oncol; 2011 May; 13(5):335-40. PubMed ID: 21596662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
